Diane Tran, MD
Advanced Heart Failure and Transplant Cardiology · Loma Linda, CANPI 1962665786
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (39.4%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. 19 manufacturers reported payments, led by Abbott at 36.1% of the total. 2025 is the largest year on record at $8,781, more than ten times the $290 reported in 2019. That places this record below the midpoint for advanced heart failure and transplant cardiology clinicians in CA, where the typical reported total is $9,367.
Across 127 payments — averaging $93.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$4K
- E.r. Squibb & Sons, L.L.C.$4K
- Abiomed$545
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$356
- AstraZeneca$352
- Biotronik Inc.$285
- plus $2K from 13 others
What the payments were for
- Consulting fees$3,84032%
- Travel & lodging$3,38328%
- Food & beverage$4,69839%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 32 | $4,304 |
| E.r. Squibb & Sons, L.L.C. | 15 | $4,284 |
| Abiomed | 15 | $545 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 9 | $356 |
| AstraZeneca | 11 | $352 |
| Biotronik Inc. | 2 | $285 |
| Boston Scientific | 3 | $255 |
| Bridgebio Pharma, Inc. | 4 | $229 |
| Boehringer Ingelheim | 3 | $178 |
| Lexicon Pharmaceuticals, Inc. | 9 | $166 |
| Paragonix Technologies, Inc. | 3 | $160 |
| Medtronic | 2 | $157 |
| Bayer | 2 | $141 |
| Actelion Pharmaceuticals US, Inc. | 1 | $131 |
| Kestra Medical Technology Services, Inc. | 2 | $88 |
| Kiniksa Pharmaceuticals International, PLC | 4 | $85 |
| Novartis | 4 | $80 |
| Pfizer | 3 | $72 |
| Novo Nordisk | 3 | $52 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- THORATEC HEARTMATE 3 LVAS IMPLANT KIT$2,460
- CARDIOMEMS$1,003
- Impella$230
- BioMonitor$164
- MitraClip$150
- LOKELMA$125
- Kerendia$125
- JARDIANCE$125
- Micra$124
- Attruby$122
- LUX-Dx Insertable Cardiac Monitor$104
- LifeVest$101
- CAMZYOS$100
How this compares
$11,921 in reported general payments places this provider in the 50th percentile of 111 advanced heart failure and transplant cardiology providers in California.
See all advanced heart failure and transplant cardiology providers in California →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| CamzyosMavacamten | 41 | $333,523 |
| JardianceEmpagliflozin | 286 | $324,737 |
| EntrestoSacubitril/Valsartan | 273 | $320,417 |
| FarxigaDapagliflozin Propanediol | 106 | $108,791 |
| EliquisApixaban | 94 | $105,693 |
| XareltoRivaroxaban | 26 | $30,408 |
| DapagliflozinDapagliflozin Propanediol | 22 | $21,298 |
| OzempicSemaglutide | 23 | $21,245 |
| Metoprolol Succinate | 413 | $4,872 |
| Bumetanide | 120 | $3,357 |
| Ranolazine ErRanolazine | 42 | $3,128 |
| Spironolactone | 356 | $2,584 |
| Carvedilol | 276 | $2,328 |
| Atorvastatin Calcium | 242 | $2,105 |
| Tacrolimus | 33 | $1,708 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| E.r. Squibb & Sons, L.L.C.Camzyos | $4,284 | $333,52341 claims |
| Boehringer IngelheimJardiance | $178 | $324,737286 claims |
| NovartisEntresto | $80 | $320,417273 claims |
| AstraZenecaFarxiga | $352 | $108,791106 claims |
| PfizerEliquis | $72 | $105,69394 claims |
| Novo NordiskOzempic | $52 | $21,24523 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 111 advanced heart failure and transplant cardiology providers in California.
Other advanced heart failure and transplant cardiology in Loma Linda
- Dmitry AbramovLoma Linda$44K
- Antoine SakrLoma Linda$16K
- Richard WrightSanta Monica$1.7M
- James Heywoodla Jolla$1.2M
- Hirsch MehtaSan Diego$494K
- Teresa de MarcoSan Francisco$366K
- Rajeev Mohanla Jolla$357K
- Marcus UreySan Diego$341K
- Munir JanmohamedSacramento$314K
- Barry GreenbergSan Diego$270K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.